NE
NEO.US NeoGenomics Inc
- Market cap
- USD 1.99B
- P/E
- -
- P/B
- 2.59x
- ROE
- -3.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is NEO.US undervalued?
Graham numberThe Graham number of NeoGenomics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
NeoGenomics Inc fundamental analysis
No fundamental analysis for NeoGenomics Inc yet.
NeoGenomics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About NeoGenomics Inc
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detectin…
Full company profileNeoGenomics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
NeoGenomics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 244M | 240M | 277M | 409M | 444M | 484M | 510M | 592M | 661M | 727M | 797M |
| Gross Profit | 110M | 102M | 127M | 197M | 186M | 187M | 188M | 245M | 290M | 283M | 359M |
| Operating Income | 2.57M | 2.90M | 10.0M | 13.0M | -14.0M | -119M | -158M | -108M | -92.1M | -66.1M | -47.9M |
| EBITDA | 25.4M | 26.6M | 31.8M | 37.6M | 28.7M | 46.5M | -82.3M | -17.6M | -1.51M | -38.7M | 36.9M |
| Net Income | -6.14M | -396K | 2.64M | 8.01M | 4.17M | -8.35M | -144M | -88.0M | -78.7M | -108M | -29.9M |
| EPS | -0.08 | 0.00 | 0.03 | 0.08 | 0.04 | -0.07 | -1.16 | -0.70 | -0.62 | -0.84 | -0.23 |
| Balance Sheet | |||||||||||
| Total Assets | 337M | 343M | 505M | 710M | 988M | 1.87B | 1.74B | 1.68B | 1.64B | 1.36B | 1.38B |
| Total Liabilities | 151M | 138M | 185M | 202M | 294M | 762M | 742M | 740M | 736M | 523M | 576M |
| Shareholders' Equity | 187M | 206M | 320M | 507M | 694M | 1.11B | 998M | 942M | 902M | 837M | 801M |
| Cash & Short-term Investments | 12.5M | 12.8M | 9.81M | 173M | 296M | 515M | 438M | 415M | 387M | 160M | 139M |
| Total Debt | 128M | 105M | 112M | 133M | 218M | 613M | 611M | 612M | 605M | 472M | 449M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 21.5M | 18.0M | 44.8M | 23.4M | 1.46M | -26.7M | -66.0M | -1.95M | 7.02M | 5.23M | 3.92M |
| Capital Expenditure | 7.54M | 13.7M | 14.3M | 20.0M | 29.1M | 64.1M | 30.9M | 28.8M | 41.1M | 27.0M | 33.3M |
| Free Cash Flow | 13.9M | 4.35M | 30.5M | 3.34M | -27.6M | -90.9M | -96.9M | -30.7M | -34.0M | -21.8M | -29.4M |
| Ratios | |||||||||||
| ROE | -3.3% | -0.2% | 0.8% | 1.6% | 0.6% | -0.8% | -14.5% | -9.3% | -8.7% | -12.9% | -3.7% |
| ROA | -1.8% | -0.1% | 0.5% | 1.1% | 0.4% | -0.4% | -8.3% | -5.2% | -4.8% | -7.9% | -2.2% |
| Net Profit Margin | -2.5% | -0.2% | 1.0% | 2.0% | 0.9% | -1.7% | -28.3% | -14.9% | -11.9% | -14.9% | -3.8% |
| Debt to Equity | 0.69x | 0.51x | 0.35x | 0.26x | 0.31x | 0.55x | 0.61x | 0.65x | 0.67x | 0.56x | 0.56x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
NeoGenomics Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | USD 9.60M | 0.10 | 363.6% |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:100 on Apr 16, 2003.
Who owns NeoGenomics Inc
- Insiders 2.68%
- Institutions 97.32%
- Public & others 0.00%
- Shares outstanding 129M
- Free float 118M
Top funds holding NEO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 7.74M | 5.98% | +0.05% | Oct 2026 |
| First Trust NYSE Arca Biotech ETF | 5.99M | 4.63% | 0.00% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 4.16M | 3.22% | +0.35% | Sep 2026 |
| Nomura Small Cap Core I | 4.08M | 3.15% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 3.30M | 2.55% | 0.00% | Oct 2026 |
| Vanguard Small Cap Index | 2.89M | 2.24% | -3.34% | Sep 2026 |
| Loomis Sayles Small Cap Growth Instl | 1.81M | 1.40% | 0.00% | Sep 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 1.61M | 1.24% | -6.10% | Sep 2026 |
| Fidelity Small Cap Index | 1.44M | 1.11% | +0.13% | Aug 2026 |
| Invesco S&P SmallCap Momentum ETF | 1.36M | 1.05% | 0.00% | Oct 2026 |
| State Street SPDR Port S&P 600 Sm CpETF | 1.18M | 0.91% | -0.05% | Oct 2026 |
| iShares Russell 2000 Value ETF | 1.11M | 0.86% | 0.00% | Oct 2026 |
| Heptagon Driehaus US Micro Cap Eq C$ Acc | 1.03M | 0.79% | 0.00% | Sep 2026 |
| Glenmede Small Cap Equity Adv | 948K | 0.73% | -31.41% | Sep 2026 |
| Vanguard Tax-Managed Small Cap Adm | 912K | 0.71% | 0.00% | Sep 2026 |
| Schroder US Mid Cap Inc | 811K | 0.63% | -1.17% | Sep 2026 |
| T. Rowe Price Small-Cap Value | 775K | 0.60% | 0.00% | Sep 2026 |
| Vanguard Russell 2000 ETF | 754K | 0.58% | -0.38% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 685K | 0.53% | +0.24% | Oct 2026 |
| Alger Small Cap Focus I | 682K | 0.53% | +17.42% | Aug 2026 |
Top institutions holding NEO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 20.9M | 16.13% | +4.56% | Jun 2026 |
| First Light Asset Management, LLC | 12.3M | 9.49% | +26.20% | Jun 2026 |
| First Trust Advisors L.P. | 10.1M | 7.82% | +64.11% | Jun 2026 |
| Greenhouse Funds LLLP | 8.57M | 6.63% | -5.78% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 8.06M | 6.23% | +5.76% | Jun 2026 |
| Vanguard Capital Management, LLC | 5.76M | 4.45% | +1.90% | Jun 2026 |
| State Street Corp | 5.36M | 4.15% | +4.76% | Jun 2026 |
| Delaware Management Holdings Inc | 5.04M | 3.89% | +45.91% | Jun 2026 |
| BRAIDWELL LP | 4.92M | 3.80% | -12.45% | Jun 2026 |
| Schroder Investment Management Group | 4.34M | 3.36% | +21.70% | Jun 2026 |
| Geode Capital Management, LLC | 3.43M | 2.65% | +6.10% | Jun 2026 |
| Millennium Management LLC | 3.08M | 2.38% | +38.55% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 2.59M | 2.00% | +7.95% | Sep 2026 |
| Loomis, Sayles & Company LP | 2.54M | 1.96% | +30.45% | Jun 2026 |
| Driehaus Capital Management LLC | 2.51M | 1.94% | +45.71% | Jun 2026 |
| Bank of America Corp | 2.44M | 1.88% | -20.23% | Jun 2026 |
| Arrowstreet Capital Limited Partnership | 2.39M | 1.85% | 0.00% | Jun 2026 |
| American Capital Management Inc | 2.24M | 1.73% | -0.59% | Jun 2026 |
| D. E. Shaw & Co LP | 2.19M | 1.70% | -47.29% | Jun 2026 |
| Samlyn Capital, LLC | 2.13M | 1.65% | -16.66% | Jun 2026 |
NeoGenomics Inc company profile
- Company name
- NeoGenomics Inc
- Ticker
- NEO.US
- Exchange
- USA Stocks
- Listed since
- Nov 2, 1999
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 2,500
- Fiscal year end
- December
- Address
- 9490 NeoGenomics Way, Fort Myers, FL, United States, 33912
- Phone
- 239 768 0600
- Website
- neogenomics.com
About NeoGenomics Inc
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
NeoGenomics Inc management
10- Mr. Anthony P. ZookCEO & Director · born 1961
- Mr. Warren StonePresident & COO · born 1973
- Ms. Elizabeth A. FloegelChief Digital & Information Officer · born 1976
- Mr. Gary PassmanChief People & Culture Officer
- Mr. Abhishek JainExecutive VP & CFO · born 1976
- Mr. Gregory D. AunanSenior VP & Chief Accounting Officer · born 1969
- Mr. Andrew Frederick Brackmann C.F.A.Vice President of Investor Relations
- Mr. Clarence Cooper Esq.Vice President of Compliance & Privacy
- Ms. Ellisa Cholapranee J.D.General Counsel
- Dr. Andrew A. Lukowiak Ph.D.Chief Innovation Officer · born 1972